Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Efficient intracellular assembly of papillomaviral vectors.
|
J Virol
|
2004
|
5.36
|
2
|
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials.
|
Lancet Oncol
|
2015
|
4.84
|
3
|
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.
|
JAMA
|
2007
|
4.66
|
4
|
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
|
J Natl Cancer Inst
|
2011
|
3.92
|
5
|
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.
|
Nat Med
|
2007
|
3.88
|
6
|
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
|
Virology
|
2004
|
3.85
|
7
|
Generation of HPV pseudovirions using transfection and their use in neutralization assays.
|
Methods Mol Med
|
2005
|
3.26
|
8
|
Maturation of papillomavirus capsids.
|
J Virol
|
2005
|
3.18
|
9
|
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.
|
Cancer
|
2008
|
3.16
|
10
|
Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1.
|
Nat Genet
|
2005
|
2.92
|
11
|
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.
|
Lancet Oncol
|
2011
|
2.85
|
12
|
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.
|
Cancer Discov
|
2011
|
2.66
|
13
|
Carrageenan is a potent inhibitor of papillomavirus infection.
|
PLoS Pathog
|
2006
|
2.65
|
14
|
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.
|
Proc Natl Acad Sci U S A
|
2006
|
2.64
|
15
|
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.
|
J Natl Cancer Inst
|
2003
|
2.58
|
16
|
Papillomaviruses infect cells via a clathrin-dependent pathway.
|
Virology
|
2003
|
2.47
|
17
|
Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.
|
Proc Natl Acad Sci U S A
|
2004
|
2.43
|
18
|
E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.
|
EMBO J
|
2004
|
2.38
|
19
|
Arrangement of L2 within the papillomavirus capsid.
|
J Virol
|
2008
|
2.37
|
20
|
Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.
|
J Virol
|
2008
|
2.37
|
21
|
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
|
Virology
|
2005
|
2.31
|
22
|
In vivo mechanisms of vaccine-induced protection against HPV infection.
|
Cell Host Microbe
|
2010
|
2.24
|
23
|
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.
|
J Virol
|
2008
|
2.22
|
24
|
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
|
Cancer Prev Res (Phila)
|
2013
|
2.17
|
25
|
DLC-1:a Rho GTPase-activating protein and tumour suppressor.
|
J Cell Mol Med
|
2007
|
2.09
|
26
|
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.
|
J Virol
|
2007
|
2.05
|
27
|
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.
|
PLoS One
|
2013
|
2.03
|
28
|
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
|
J Natl Cancer Inst
|
2009
|
1.95
|
29
|
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
|
Vaccine
|
2011
|
1.91
|
30
|
The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding.
|
Proc Natl Acad Sci U S A
|
2009
|
1.90
|
31
|
Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.
|
Proc Natl Acad Sci U S A
|
2007
|
1.87
|
32
|
Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.
|
J Virol
|
2008
|
1.73
|
33
|
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
|
Vaccine
|
2006
|
1.73
|
34
|
Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model.
|
J Natl Cancer Inst
|
2011
|
1.71
|
35
|
Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.
|
J Infect Dis
|
2009
|
1.70
|
36
|
Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
|
Vaccine
|
2012
|
1.61
|
37
|
Understanding and learning from the success of prophylactic human papillomavirus vaccines.
|
Nat Rev Microbiol
|
2012
|
1.58
|
38
|
Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis.
|
PLoS Genet
|
2007
|
1.55
|
39
|
Human alpha-defensins block papillomavirus infection.
|
Proc Natl Acad Sci U S A
|
2006
|
1.48
|
40
|
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles.
|
J Immunol
|
2002
|
1.48
|
41
|
p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB.
|
Oncogene
|
2003
|
1.45
|
42
|
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
|
J Infect Dis
|
2003
|
1.40
|
43
|
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
|
J Clin Invest
|
2012
|
1.37
|
44
|
Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection.
|
J Virol
|
2013
|
1.29
|
45
|
Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.
|
Vaccine
|
2005
|
1.19
|
46
|
Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.
|
Cancer Res
|
2012
|
1.14
|
47
|
Vaccines to prevent infections by oncoviruses.
|
Annu Rev Microbiol
|
2010
|
1.14
|
48
|
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
|
Vaccine
|
2005
|
1.14
|
49
|
The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis.
|
Cancer Cell
|
2009
|
1.14
|
50
|
A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.
|
Clin Vaccine Immunol
|
2012
|
1.13
|
51
|
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
|
Virology
|
2006
|
1.11
|
52
|
Prognostic implications of HPV in oropharyngeal cancer.
|
N Engl J Med
|
2010
|
1.11
|
53
|
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells.
|
Clin Immunol
|
2003
|
1.03
|
54
|
Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.
|
Proc Natl Acad Sci U S A
|
2003
|
1.02
|
55
|
Getting stronger: the relationship between a newly identified virus and Merkel cell carcinoma.
|
J Invest Dermatol
|
2009
|
1.01
|
56
|
Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus.
|
J Virol
|
2004
|
1.01
|
57
|
Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
|
Proc Natl Acad Sci U S A
|
2011
|
1.00
|
58
|
Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.
|
J Infect Dis
|
2013
|
0.99
|
59
|
Prospects for cervical cancer prevention by human papillomavirus vaccination.
|
Cancer Res
|
2006
|
0.98
|
60
|
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).
|
Vaccine
|
2012
|
0.97
|
61
|
A new link between Fanconi anemia and human papillomavirus-associated malignancies.
|
J Natl Cancer Inst
|
2003
|
0.96
|
62
|
Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells.
|
Eur J Immunol
|
2005
|
0.94
|
63
|
In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system.
|
Cancer Prev Res (Phila)
|
2011
|
0.93
|
64
|
Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients.
|
J Immunol
|
2009
|
0.93
|
65
|
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
|
Clin Vaccine Immunol
|
2007
|
0.92
|
66
|
Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica.
|
J Infect Dis
|
2012
|
0.92
|
67
|
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
|
J Virol
|
2013
|
0.92
|
68
|
Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.
|
Cancer Res
|
2012
|
0.90
|
69
|
Regulation of cell morphology and adhesion by the tuberous sclerosis complex (TSC1/2) gene products in human kidney epithelial cells through increased E-cadherin/beta-catenin activity.
|
Mol Carcinog
|
2003
|
0.89
|
70
|
Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species.
|
Virology
|
2012
|
0.89
|
71
|
The expression of glyceraldehyde-3-phosphate dehydrogenase associated cell cycle (GACC) genes correlates with cancer stage and poor survival in patients with solid tumors.
|
PLoS One
|
2013
|
0.88
|
72
|
Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization.
|
J Virol
|
2013
|
0.87
|
73
|
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
|
Hum Vaccin Immunother
|
2013
|
0.87
|
74
|
Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies.
|
Clin Vaccine Immunol
|
2007
|
0.87
|
75
|
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.
|
J Immunol
|
2011
|
0.86
|
76
|
In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells.
|
BMC Cancer
|
2013
|
0.84
|
77
|
Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.
|
Am J Epidemiol
|
2014
|
0.82
|
78
|
HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.
|
J Clin Invest
|
2016
|
0.81
|
79
|
Virus infection and human cancer: an overview.
|
Recent Results Cancer Res
|
2014
|
0.81
|
80
|
The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1.
|
Blood
|
2010
|
0.81
|
81
|
Immune readouts may have prognostic value for the course of merkel cell carcinoma, a virally associated disease.
|
J Clin Oncol
|
2011
|
0.75
|
82
|
Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
|
Hum Vaccin Immunother
|
2014
|
0.75
|